Terezaki Eleni, Calissendorff Jan, Mannheimer Buster, Lindh Jonatan D, Falhammar Henrik
Department of Endocrinology, Karolinska University Hospital, SE-17176 Stockholm, Sweden.
Centre for Inherited Metabolic Diseases, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
J Endocr Soc. 2025 Apr 2;9(5):bvaf058. doi: 10.1210/jendso/bvaf058. eCollection 2025 May.
Adrenal tumors (ATs) are highly uncommon in children and adolescents, and more information on these tumors is needed.
The aim of this study was to describe the tumor incidence, patient and tumor characteristics, treatment, and mortality in pediatric patients with ATs.
This is a Swedish nationwide, register-based, retrospective study. All patients up to 21 years old diagnosed between 2005 and 2019 with an AT were identified through national registers and then manually reviewed. Age-, sex-, and municipality-matched controls in a ratio 4:1 were selected from the total population register.
In total, 230 patients were included (and 920 controls), with an annual incidence of 6.20 new ATs per million for individuals up to 21 years old. The median age was 6.0 years (interquartile range, 1.0-17.70), with 120 (52.2%) being boys. Regarding tumor biology, 132 (57.4%) were malignant, 77 (33.5%) benign, and 21 (9.1%) were undetermined. There were at least 39 (16.9%) hormonally active ATs recognized as either pheochromocytomas, adrenocortical carcinomas, or benign functional adenomas. Patients with malignant tumors were younger than patients with benign tumors (mean age 2 vs 18, < .001). Among patients with malignant ATs, the mortality reached 33.3% during a follow-up period of up to 15 years. Patients who were younger and received less aggressive treatments had better overall survival. Mortality was increased in all patients with malignant ATs compared to controls ( < .0001). Mortality was similar between patients with benign ATs and controls ( > .05).
Although rare, most identified tumors were malignant and associated with high mortality.
肾上腺肿瘤(ATs)在儿童和青少年中极为罕见,因此需要更多关于这些肿瘤的信息。
本研究旨在描述儿童肾上腺肿瘤患者的肿瘤发病率、患者及肿瘤特征、治疗情况和死亡率。
这是一项基于瑞典全国登记系统的回顾性研究。通过国家登记系统识别出2005年至2019年间诊断为肾上腺肿瘤的所有21岁及以下患者,然后进行人工审核。从总人口登记册中按4:1的比例选取年龄、性别和市政区域匹配的对照。
总共纳入了230例患者(以及920例对照),21岁及以下个体的肾上腺肿瘤年发病率为每百万6.20例新发病例。中位年龄为6.0岁(四分位间距为1.0 - 17.70),其中120例(52.2%)为男性。关于肿瘤生物学特性,132例(57.4%)为恶性,77例(33.5%)为良性,21例(9.1%)未确定。至少有39例(16.9%)激素活性肾上腺肿瘤被认定为嗜铬细胞瘤、肾上腺皮质癌或良性功能性腺瘤。恶性肿瘤患者比良性肿瘤患者年轻(平均年龄2岁对18岁,P <.001)。在恶性肾上腺肿瘤患者中,长达15年的随访期内死亡率达到33.3%。年龄较小且接受的治疗不太积极的患者总体生存率更好。与对照组相比,所有恶性肾上腺肿瘤患者的死亡率均有所增加(P <.0001)。良性肾上腺肿瘤患者与对照组的死亡率相似(P >.05)。
尽管罕见,但大多数确诊的肿瘤为恶性且死亡率高。